Fluvoxamine:

Correct Answer: D

Rationale: Fluvoxamine inhibits CYP450 enzymes. It is not an MAOI, has weak anticholinergic effects, and does not require weekly blood counts.

Correct Answer: C

Rationale: Valproate belongs to the category class of anticonvulsants, which means it is primarily used to treat seizures and epilepsy. Additionally, valproate also has properties that make it effective in the treatment of vascular headaches, such as migraines. It is not an anticoagulant, antianxiety medication like benzodiazepines, or a mood stabilizer.

Correct Answer: B

Rationale: Epidermal growth factor receptor (EGFR) inhibitors commonly cause skin-related side effects, such as rash, dryness, and paronychia (nail inflammation). These side effects can lead to tissue injury and discomfort, impacting the patient's quality of life. While bone marrow suppression and reduced platelet activity are concerns with other chemotherapies, they are less common with EGFR inhibitors. Alopecia is also less frequently associated with these drugs. The nurse should prioritize monitoring and managing skin-related side effects to prevent complications and ensure patient comfort.

Correct Answer: B

Rationale: Fluphenazine, a high-potency first-generation antipsychotic, strongly blocks D2 receptors, requiring lower doses for efficacy but increasing EPS risk (e.g., dystonia, parkinsonism) due to intense dopamine antagonism in the nigrostriatal pathway. Thioridazine and chlorpromazine, low-potency first-generation drugs, have weaker D2 affinity, causing more sedation and anticholinergic effects than EPS. Quetiapine, a second-generation antipsychotic, has low D2 potency and minimal EPS. Clozapine avoids EPS with broad receptor activity. Fluphenazine's potency, measured by dose equivalence and clinical data, correlates with its elevated EPS risk, distinguishing it here.

Correct Answer: D

Rationale: Fluvoxamine inhibits CYP450 enzymes. It is not an MAOI, has weak anticholinergic effects, and does not require weekly blood counts.